Leica Biosystems of Newcastle upon Tyne, England, has acquired privately held Kreatech Diagnostics of Amsterdam, a provider of DNA fluorescence in situ hybridization probes and target labeling reagents, for an undisclosed amount. Kreatech will join Leica Biosystems’ Advanced Staining business unit, which is based in the UK. The combined business will develop targeted biomarker menus for Leica’s instrument platforms. The acquisition will enable a renewed focus on cytogenetics and anatomic pathology as well as on personalized medicine at research and drug development companies. Leica Biosystems is a provider of ThermoBrite and Bond systems for labeling tissue specimens for diagnostic interpretation in cytogenetics and pathology laboratories.